Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny nerve zap could reveal secrets of blood pressure control

NCT ID NCT07013929

Knowledge-focused Sponsor: Medtronic Vascular Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new way to understand how nerves in the kidney affect blood pressure. About 19 adults with high blood pressure will receive mild electrical stimulation to kidney nerves before and after a procedure that quiets those nerves. The goal is to learn how the body responds, not to provide treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 19 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 20 - 70 years of age 2. Office SBP ≥150 mmHg and \<180 mmHg and DBP ≥90 mmHg 3. Individual is prescribed with one, two, or three antihypertensive medication classes 4. 24-hour ABPM average of SBP ≥135 and \<170 mmHg at Baseline Exclusion Criteria: 1. Prior renal denervation. 2. Individual lacks appropriate renal artery Anatomy 3. Has a renal artery stent 4. Individual has an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m2 5. Individual is taking SGLT2 inhibitors or GLP-1 agonists 6. Individual requires chronic oxygen support or mechanical ventilation 7. Primary pulmonary hypertension. 8. Secondary cause of hypertension 9. Pregnant, nursing or planning to become pregnant during the study. 10. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement 11. Individual is currently taking anti-mineralocorticoid drugs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder hypertensive disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Hypertension Vascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hippokration General Hospital of Athens

    RECRUITING

    Athens, 11527, Greece

  • University Hospital Galway

    RECRUITING

    Galway, H91 YR71, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.